Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib–TACE sequential therapy followed by liver resection in intermediate-stage hepatocellular carcinoma
jRCTs061220007Recruiting
- Sponsor
- Hiroshima Surgical Study Group of Clinical Oncology
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Hiroshima Surgical Study Group of Clinical Oncology. Primary endpoint: Surgical resection rate after preoperative therapy. Started Jul 2022; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs061220007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061220007.